object
highli
pathogen
virus
ebov
threat
routin
laboratori
worker
inactiv
procedur
triton
andor
heat
current
recommend
unknown
effect
accuraci
serolog
test
furthermor
viru
inactiv
triton
shown
ineffect
serum
studi
aim
demonstr
viru
inactiv
serum
triton
maintain
accuraci
serolog
test
method
panel
serolog
test
run
patient
serum
sampl
treatment
triton
heat
inactiv
c
h
mean
differ
measur
bia
calcul
appli
blandealtman
method
determin
effect
viru
inactiv
herp
simplex
viru
spike
medium
contain
serum
treat
triton
infecti
titr
determin
vero
cell
result
serolog
measur
show
good
agreement
control
sampl
treat
triton
estim
bia
n
n
respect
discord
qualit
result
rare
convers
heat
inactiv
alon
combin
triton
trigger
bia
n
n
respect
triton
complet
inactiv
serum
triton
fail
serum
conclus
unlik
heat
inactiv
triton
enabl
accur
serolog
test
complet
inactiv
serum
simpl
method
could
allow
safe
routin
serolog
diagnost
highrisk
patient
mm
remi
clin
microbiol
infect
highli
pathogen
virus
ebov
sar
coronaviru
continu
threat
clinic
laboratori
worker
current
epidem
lassa
viru
nigeria
one
latest
concern
european
hospit
must
prepar
deal
potenti
infect
return
travel
microbiolog
diagnosi
virus
perform
requir
biosafeti
measur
special
laboratori
blood
sampl
patient
arriv
emerg
room
often
sent
directli
routin
laboratori
biosafeti
level
low
earli
symptom
caus
highli
pathogen
virus
usual
nonspecif
requir
differenti
diagnosi
infecti
diseas
malaria
dengu
fever
hiv
hbv
cmv
infect
confirm
case
potenti
long
stay
intens
care
increas
risk
secondari
infect
invas
fungal
infect
diagnosi
patholog
remain
mostli
base
serolog
polymeras
chain
reaction
pcr
altern
diagnost
method
safe
perform
infecti
sampl
howev
appropri
viraem
phase
inactiv
highli
pathogen
virus
serum
world
health
organ
us
center
diseas
control
prevent
cdc
recommend
chemic
inactiv
triton
heat
inactiv
c
min
combin
thereof
triton
nonion
surfact
disrupt
lipid
membran
envelop
virus
without
affect
protein
therefor
wide
use
combin
tri
nbutyl
phosphat
tnbp
solventedeterg
inactiv
procedur
plasma
product
transfus
besid
triton
success
evalu
haematolog
clinic
chemistri
malaria
rapid
diagnost
test
rdt
accuraci
immunoassay
triton
treatment
serum
partial
assess
decreas
sensit
report
heat
inactiv
compat
detect
ebovspecif
igg
igm
viral
antigen
howev
clinic
chemistri
studi
show
protein
measur
especi
enzymat
activ
measur
mildli
sever
affect
heat
easili
applic
inactiv
method
sd
treatment
unfortun
denatur
protein
suit
serolog
clinic
chemistri
test
efficaci
heat
inactiv
demonstr
sever
envelop
virus
includ
haemorrhag
fever
virus
concern
deterg
complet
inactiv
hiv
achiev
triton
wherea
ebov
treatment
triton
led
incomplet
inactiv
log
infect
reduct
besid
recent
claim
inactiv
potenti
triton
annul
serum
inactiv
test
inde
perform
ebov
herp
simplex
viru
type
serum
viral
inactiv
triton
succeed
medium
less
serum
suggest
factor
serum
interfer
deterg
effect
practic
triton
concentr
often
increas
ensur
higher
level
safeti
although
inactiv
data
support
choic
thu
remain
determin
higher
concentr
triton
overcom
effici
issu
serum
object
studi
assess
accuraci
wide
rang
serolog
test
chemic
thermal
inactiv
serum
triton
final
concentr
andor
heat
inactiv
c
min
select
promis
inactiv
method
addit
inactiv
test
perform
triton
medium
contain
serum
hypothes
tenfold
increas
triton
final
concentr
might
allow
complet
viru
inactiv
serum
human
blood
sampl
obtain
routin
patient
serolog
test
institut
infecti
diseas
univers
bern
switzerland
suspicion
highli
pathogen
viru
infect
patient
sera
use
studi
store
c
less
year
retrospect
identifi
use
electron
databas
institut
infecti
diseas
univers
bern
accord
serolog
test
origin
perform
result
obtain
select
serum
sampl
anonym
test
serolog
test
origin
inform
consent
use
anonym
leftov
patient
materi
waiv
procedur
approv
canton
research
ethic
committe
bern
switzerland
basecno
chemic
inactiv
procedur
consist
mix
patient
serum
pb
triton
work
solut
pleas
see
supplementari
materi
sampl
incub
min
room
temperatur
final
concentr
triton
precis
sampl
treat
pb
triton
addit
thermal
inactiv
incub
c
h
tabl
top
thermoblock
without
shake
sampl
kept
maximum
h
c
use
differ
serolog
test
pretreat
sampl
analys
parallel
follow
method
hiv
hcv
hbv
ebv
cmv
toxoplasmosi
marker
ag
total
ig
igm
andor
igg
analys
system
abbott
diagnost
fulli
autom
immunoanalys
base
chemiluminesc
microparticl
immunoassay
cmia
antibodi
brucella
speci
igm
igg
test
indirect
chemiluminesc
immunoassay
clia
anoth
fulli
autom
analys
vircel
granada
spain
aspergillosi
galactomanan
test
aspergillu
ag
biorad
hercul
ca
usa
perform
manual
antibodi
dengu
viru
igm
igg
detect
manual
elisa
euroimmun
ei
reactiv
francisella
tularensi
evalu
rapid
test
virapid
tularemia
viracel
microbiologist
microagglutin
test
use
f
tularensi
ag
becton
dickinson
franklin
lake
nj
usa
manual
test
perform
accord
manufactur
instruct
pleas
see
supplementari
materi
detail
concentr
stock
spike
mem
contain
fb
pure
human
serum
seroneg
donor
mix
triton
work
solut
incub
h
room
temperatur
final
concentr
triton
precis
final
concentr
serum
human
serum
fb
initi
viral
titr
sampl
rang
tcid
ml
excess
deterg
remov
inactiv
viral
sampl
pleas
see
supplementari
materi
sampl
titrat
vero
cell
pleas
see
supplementari
materi
experi
repeat
twice
control
contain
triton
without
viru
also
filter
titrat
evalu
cytotox
caus
residu
deterg
graphpad
prism
version
use
plot
analys
data
serolog
test
result
blandealtman
plot
construct
evalu
differ
treat
untreat
sampl
percentag
differ
mean
bia
serolog
result
chemic
inactiv
sampl
addit
analys
deme
linear
regress
model
spearman
correl
coeffici
calcul
data
pass
dagostino
pearson
normal
test
assess
agreement
qualit
item
cohen
weight
kappa
coeffici
calcul
graphpad
quickcalc
titr
logconvert
obtain
nearnorm
distribut
statist
analysi
oneway
analysi
varianc
anova
perform
follow
dunnett
post
test
compar
multipl
group
control
group
p
valu
consid
signific
ns
p
consid
highli
signific
patient
serum
sampl
receiv
routin
serolog
test
chemic
inactiv
triton
final
concentr
compar
pbstreat
control
sever
elisabas
serolog
assay
tabl
sampl
care
select
cover
wide
rang
concentr
qualit
result
assess
sampl
fals
result
rate
frr
calcul
comput
falseneg
falseposit
result
compar
control
test
bia
test
result
compar
control
mean
differ
versu
averag
treatment
triton
treatment
triton
tabl
fig
b
good
agreement
confirm
statist
method
includ
deme
linear
regress
spearman
correl
coeffici
tabl
autom
chemiluminesc
assay
cmia
clia
gave
similar
result
manual
perform
elisa
one
discord
qualit
result
observ
dengu
igg
treatment
triton
concern
sampl
around
borderlin
cutoff
tabl
overal
fals
result
rate
treatment
triton
tabl
increas
concentr
triton
led
nonsignific
increas
fals
result
rate
tabl
accordingli
serolog
result
substanti
alter
fig
fals
result
concern
borderlin
dengu
igg
sampl
one
sampl
aspergillu
test
valu
around
posit
cutoff
one
sampl
hbv
antihbc
total
ig
chang
weak
posit
control
neg
triton
tabl
contrast
thermal
inactiv
incub
serum
sampl
c
h
yield
aberr
serolog
test
result
mean
bia
increas
combin
triton
tabl
fig
sinc
result
fulfil
assumpt
homoscedast
fig
regress
analysi
perform
relev
chang
seen
cmv
igg
bias
tabl
accordingli
high
fals
result
rate
observ
assay
averag
heat
inactiv
combin
treatment
tabl
hiv
antigen
antibodi
hbv
hb
ag
igg
test
result
howev
remain
rel
unaffect
heat
inactiv
minim
bia
discord
qualit
result
tabl
addit
elisabas
assay
analys
perform
rapid
test
microagglutin
test
diagnosi
tularaemia
chemic
thermal
inactiv
serum
sampl
tabl
triton
effect
accuraci
test
triton
howev
yield
accept
rapid
test
result
disturb
microagglutin
result
end
titr
affect
sever
prozon
partial
agglutin
effect
observ
heat
inactiv
yield
poor
rapid
test
poor
microagglutin
result
mani
prozon
effect
evalu
inactiv
potenti
triton
envelop
virus
chose
model
viru
hsv
inde
prototyp
envelop
viru
grow
easili
high
titr
rapid
accur
infect
assay
avail
reason
wide
use
inactiv
studi
variou
deterg
sinc
recent
shown
serum
annul
inactiv
effect
triton
perform
assay
human
serum
medium
contain
serum
previous
shown
triton
could
complet
inactiv
medium
contain
serum
titr
reduct
least
log
effect
serum
fig
contrari
triton
concentr
led
complet
inactiv
serum
titr
reduct
least
log
fig
recent
event
includ
ebola
lassa
outbreak
west
africa
two
case
and
hantaviru
infect
return
travel
hospit
drew
attent
issu
regard
biosafeti
laboratori
worker
optim
diagnost
highrisk
patient
routin
laboratori
notic
lack
protocol
viru
inactiv
lack
data
regard
effect
inactiv
accuraci
serolog
test
demonstr
heat
inactiv
suitabl
method
serolog
diagnosi
infecti
diseas
contrari
routin
elisabasedserolog
test
rapid
test
accur
perform
treatment
triton
final
concentr
quantit
qualit
result
remain
rel
unaffect
fals
result
mostli
concern
borderlin
sampl
result
prompt
studi
effect
triton
clinic
chemistri
paramet
haematolog
test
malaria
test
triton
test
far
recent
publish
triton
suffici
inactiv
high
concentr
serum
increas
triton
final
concentr
howev
led
complet
inactiv
serum
sampl
primordi
import
safeti
laboratori
worker
consid
receiv
process
undilut
serum
sampl
potenti
infecti
sinc
triton
exert
inactiv
effect
level
viral
envelop
complet
inactiv
triton
suggest
envelop
virus
hiv
influenza
sar
ebov
could
also
complet
inactiv
procedur
remain
howev
test
especi
ebov
rather
stabl
viru
preliminari
result
ebov
inactiv
triton
min
promis
proven
inactiv
method
combin
triton
heat
ebov
unfortun
compat
serolog
diagnosi
limit
molecular
diagnosi
moreov
although
combin
allow
detect
ebovspecif
igg
igm
studi
suggest
inactiv
procedur
use
ebov
serolog
evalu
compar
inactiv
triton
alon
proven
effici
envelop
virus
gener
simpl
inactiv
procedur
base
singl
pipet
step
could
implement
basic
microbiolog
laboratori
field
diagnost
outbreak
highli
pathogen
virus
safe
rapid
diagnosi
primordi
import
initi
step
ad
deterg
serum
sampl
howev
requir
train
personnel
rigor
safeti
practic
biosafeti
cabinet
level
triton
long
histori
usag
diagnost
procedur
nevertheless
unknown
high
concentr
deterg
could
potenti
affect
routin
laboratori
analys
anoth
limit
broad
usag
triton
consist
environment
concern
reagent
soon
forbidden
europ
endocrin
disrupt
effect
aquat
organ
restrict
usag
welldefin
procedur
appropri
wast
treatment
solut
probabl
still
possibl
futur
ecofriendli
altern
lauryldimethylamin
noxid
ldao
shown
exhibit
effect
viru
inactiv
broad
rang
protein
concentr
need
evalu
differ
virus
condit
tcid
ml
pb
unfilt
pb
filter
triton
filter
triton
filter
serum
serum
ns
ns
ns
fig
influenc
serum
concentr
chemic
inactiv
herp
simplex
viru
type
reduct
titr
sampl
contain
either
fetal
bovin
serum
fb
human
serum
treatment
triton
h
room
temperatur
control
receiv
equival
amount
pb
titrat
sampl
filtrat
membran
remov
residu
triton
unfilt
pb
control
shown
account
eventu
viru
loss
filter
tcid
ml
titr
present
mean
sd
determin
three
independ
experi
replic
per
experi
abbrevi
herp
simplex
viru
type
tcid
tissu
cultur
infecti
dose
conclus
show
addit
triton
serum
sampl
enabl
complet
inactiv
compat
accur
result
wide
rang
routin
serolog
test
studi
provid
basi
develop
safe
serolog
assay
rapid
accur
differenti
diagnosi
infecti
diseas
patient
suspect
confirm
infect
highli
pathogen
virus
author
declar
conflict
interest
author
declar
extern
fund
